December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Autobahn Therapeutics

News headline image
Autobahn Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics Presents New Preclinical Data at ACNP Annual Meeting Supporting Novel Restorative Neuroplasticity Mechanism of Elunetirom
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics to Participate in Evercore’s Emerging Private Biotech Conference
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics to Participate in Jefferies Global Healthcare Conference
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics Announces Presentation of ABX-002 Phase 1 Clinical Results at the 2025 ASCP Annual Meeting
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics Announces Initiation of Phase 2 Trial of ABX-002 as an Adjunctive Treatment for Bipolar Depression
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics Announces FDA Clearance of IND Application for ABX-002 as an Adjunctive Treatment for Bipolar Depression
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics Announces Initiation of its AMPLIFY Phase 2 Trial of ABX-002 as an Adjunctive Treatment for Major Depressive Disorder
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics Completes Oversubscribed $100 Million Series C Financing to Advance Pipeline of Novel Therapeutics for Depression and Other CNS Disorders
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics to Participate in the Leerink Partners Biopharma Private Company Connect
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics to Participate in the Jefferies Global Healthcare Conference
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics to Present at the Stifel 2024 Virtual CNS Days
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics to Participate in Upcoming Investor Conferences
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics to Present at the Stifel 2023 Healthcare Conference
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics Announces Positive Topline Results from Phase 1 Study of ABX-002, its Lead Oral Treatment for Major Depressive Disorder
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics to Present at Upcoming Investor Conferences
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics Completes Dosing in its Phase 1 Multiple-ascending Dose Study of ABX-002 for Major Depressive Disorder and Reports Company Progress
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics Advances ABX-002, its Lead Oral Treatment for Major Depressive Disorder, into Multi-Ascending Dose Portion of Phase 1 Trial
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics to Present at the Stifel 2023 Virtual CNS Days
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ABX-002 for the Treatment for Major Depressive Disorder
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics Announces Successful Financing to Support Strategic Advancement of ABX-002 for Treatment Resistant Depression
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics Announces Emerging Preclinical Data Demonstrating Ability of CNS-Delivered Thyromimetics to Promote Remyelination
From Autobahn Therapeutics
Via Business Wire
News headline image
Autobahn Therapeutics Announces New Preclinical Data Supporting its Novel Brain-Targeting Platform for the Development of Therapeutics for CNS Disorders
From Autobahn Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.